Abbott Laboratories (Pakistan) Limited reported a strong financial performance for the nine months ended September 30, 2026
Filed as: Financial Results for the Quarter Ended September 30, 2026
Summary
Abbott Laboratories (Pakistan) Limited reported a strong financial performance for the nine months ended September 30, 2026, with net profit reaching Rs 6.68 billion, a significant increase from the prior period.
Read the original filingFigures in the filing
| Item | This period | Period before | Change |
|---|---|---|---|
| Net Sales | PKR 58.66 billion | PKR 56.23 billion | +4.3% |
| Net Profit | PKR 6.68 billion | PKR 5.37 billion | +24.6% |
| Gross Profit | PKR 22.21 billion | PKR 19.34 billion | +14.9% |
| Basic and Diluted EPS | PKR 68.28 | PKR 54.81 | +24.6% |
| Cash and Cash Equivalents | PKR 10.37 billion | PKR 13.34 billion | -22.2% |
Amounts are in Pakistani rupees as stated in the filing (M = million, B = billion).
What the filing says
- Net sales increased to Rs 58.66 billion, up from Rs 56.23 billion in the prior period, driven by strong local sales.
- Net profit for the period rose to Rs 6.68 billion, a 24.58% increase from Rs 5.37 billion in the prior period.
- Basic and diluted earnings per share improved to Rs 68.28 from Rs 54.81, reflecting enhanced profitability.
Abbott Laboratories (Pakistan) Limited (ABOT) on Nafa
Last price Rs 1,000.00 · Pharmaceuticals · You can own ABOT shares from your phone.
More ABOT announcements
Source: Abbott Laboratories (Pakistan) Limited's filing with the Pakistan Stock Exchange. The summary and figures on this page are extracted from the filing by software and can contain errors; the filing itself is the record. This page describes the filing. It is not investment advice and Nafa does not recommend any stock. Investing in securities involves risk, including possible loss of principal.